Form 8-K

8-K — Longeveron Inc.

Accession: 0001213900-26-091677

Filed: 2026-08-19

Period: 2026-08-17

CIK: 0001721484

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — ea0302723-8k_longeveron.htm (Primary)

EX-10.1 — LETTER AGREEMENT, DATED AUGUST 17, 2026 (ea030272301ex10-1.htm)

EX-99.1 — PRESS RELEASE (ea030272301ex99-1.htm)

GRAPHIC (ea030272301_ex10-1img1.jpg)

GRAPHIC (ea030272301_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302723-8k_longeveron.htm · Sequence: 1

false

0001721484

2026-08-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 17, 2026

Longeveron Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40060

47-2174146

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1951 NW 7th Avenue, Suite 520, Miami, Florida

33136

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (305) 909-0840

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.001 par value per share

LGVN

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate

by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial

accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election

of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Longeveron Inc. (the

“Company”) has appointed Nirav S. Jhaveri to serve as Chief Financial Officer, principal financial officer and principal accounting

officer of the Company, effective August 17, 2026 (the “Effective Date”).

Mr. Jhaveri, age

48, has over 25 years of biopharma and biotech leadership experience across public and private sectors, including experience as the

Chief Financial Officer of gene-therapy and biotech companies. Mr. Jhaveri most recently served as an independent strategic advisor

to select early-stage biotech companies where he advised the companies’ Chief Executive Officers on capital markets insights,

corporation position, investor targeting, and fundraising activities. Prior to that time, Mr. Jhaveri served as Chief Financial

Officer of Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company, from February 2024 to June 2025, Insilico

Medicine, a global artificial intelligence-driven biotech company from 2021 to 2023, and Journey Medical Corporation (Nasdaq: DERM,

although pre-IPO during Mr. Jhaveri’s tenure), a commercial-stage pharmaceutical company from 2020 to 2021. Mr. Jhaveri

received his B.A. from University of Pennsylvania and his MBA from New York University.

Marie Washburn, who has

been serving as Chief Financial Officer of the Company will remain with the Company in her prior

role of Vice President and Corporate Controller.

In connection with his

appointment, Mr. Jhaveri has entered into a Letter Agreement (the “Agreement”) with the Company, pursuant to which he

will be entitled to receive an initial base salary of $400,000 per year, and is eligible to participate in the Company’s performance-based

annual cash incentive plan, with an award target equal to forty-five percent (45%) of his base salary, as well as short and long-term

equity incentive awards pursuant to the terms of the Company’s Fourth Amended and Restated 2021 Incentive Award Plan (or any successor

plan thereto). As of the Effective Date, Mr. Jhaveri will receive an equity award of 300,000 Restricted Stock Units which will vest quarterly

over a three-year period.

Under the Agreement, Mr. Jhaveri will also be

eligible for participation in standard Company employee benefit programs as well as termination and severance benefits. The foregoing

description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1

to this Current Report on Form 8-K.

There are no other arrangements

or understandings between Mr. Jhaveri and the Company or any other persons, pursuant to which Mr. Jhaveri was selected as Chief Financial

Officer of the Company. Mr. Jhaveri has no family relationships with any director, executive officer or person nominated or chosen by

the Company to become a director or executive officer of the Company. There have been no transactions since the beginning of the Company’s

last fiscal year, or currently proposed, in which the Company was or is to be a participant and in which Mr. Jhaveri had or will have

a direct or indirect material interest that are required to be disclosed under Item 404(a) of Regulation S-K.

A copy of the press release announcing the transition described herein

is attached to this report as Exhibit 99.1 and is hereby incorporated by reference.

Item 9.01. Financial

Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1

Letter Agreement, dated August 17, 2026

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LONGEVERON INC.

Date: August 19, 2026

/s/ Stephen Willard

Name:

Stephen Willard

Title:

Chief Executive Officer

EX-10.1 — LETTER AGREEMENT, DATED AUGUST 17, 2026

EX-10.1

Filename: ea030272301ex10-1.htm · Sequence: 2

Exhibit 10.1

August 17, 2026

Dear Nirav:

This letter agreement

(this “Agreement”) sets forth the terms and conditions of your (referred to as “you” or “your”

or “executive”) employment with Longeveron Inc. (the “Company”), which shall be effective as of August

17, 2026 (the “Effective Date”). This Agreement will govern your employment with the Company following the Effective

Date on the following terms and conditions:

1. Term. The term of your employment with the Company

will terminate upon delivery to you by the Company of notice to such effect, which notice may be given for any or no reason, or upon

your earlier resignation, death or Disability. You acknowledge that no provision contained in this Agreement will entitle you to remain

in the employment of the Company for any specific period of time or affect the right of the Company to terminate your employment hereunder

at any time for any reason, subject to compliance with the termination provisions set forth herein. The period during which you are employed

by the Company pursuant to this Agreement shall be referred to as the “Term.” For purposes of this Agreement, “Disability”

shall mean your inability, due to physical or mental incapacity, to perform the essential functions of your job, for one hundred eighty

(180) days out of any three hundred sixty-five (365) day period or one hundred twenty (120) consecutive days or receiving any disability

benefits under a Company plan for a period of one hundred twenty (120) consecutive days or longer.

2. Position, Duties and Reporting. Your position

will be Chief Financial Officer of the Company, and you will report directly to the Chief Executive Officer (the “CEO”) of

the Company. You shall be employed by the Company on a full-time basis and shall perform such duties and responsibilities on behalf of

the Company as are consistent with your position, as may be designated from time to time by the CEO. You will be required to devote all

of your business time to the business and affairs of the Company and to the promotion of its interests. Notwithstanding the foregoing,

you may engage in other activities such as personal investments or business ventures that do not involve a conflict of interest with

Company or civic and charitable activities, so long as: (i) such activities do not interfere or conflict with your duties and obligations

hereunder and (ii) such activities are disclosed in advance to the Company. In addition, you shall be permitted to serve as a director

on up to two (2) other publicly-traded company’s Board of Directors, in addition to current not-for-profit Board of Director positions,

so long as they do not compete with Company and subject to your prior disclosure and consent of the CEO.

3. Compensation and Benefits.

a. Base Salary. During the Term, your annual base salary

will be Four Hundred Thousand Dollars ($400,000.00) per year and will be payable in accordance with the Company’s regular payroll

practices, less the applicable taxes and elective or other necessary withholdings or deductions. Your base salary is subject to review

and adjustment on an annual basis, as determined by the CEO, with review and approval as may be required by the Compensation Committee

of the Board of Directors (the “Compensation Committee”) and/or the Board.

b. Annual Cash Bonus. During the Term, you will be eligible

for an annual cash bonus pursuant to the Company’s annual cash bonus program. Your initial aggregate target cash bonus will be

in an amount of 45% of your base salary (“Target Bonus”). With respect to the Target Bonus, eighty percent (80%) will be

based upon the achievement level of the agreed upon corporate goals established by the CEO, with input from the C-Suite and approved

by the Compensation Committee and/or the Board for the applicable fiscal year, and twenty percent (20%) shall be based on the achievement

level of individual performance criteria established by the CEO. The actual amount of any bonus earned shall be determined by the CEO,

with review and approval as may be required by the Compensation Committee and/or the Board, based on achievement of the applicable performance

criteria and any additional discretionary considerations during the applicable fiscal year. Except as otherwise provided herein, you

will be entitled to receive any earned bonus for a fiscal year of the Company following certification of the same by the CEO to the degree

to which the applicable performance criteria have been met, and payout of any such bonus shall occur no later than March 31 of the year

following the applicable fiscal year.

c. Equity Incentive Awards. Upon assuming the CFO role

with the Company, you shall be awarded 300,000 Restricted Stock Units (“RSUs”), which shall be awarded on August 17, 2026,

and shall vest quarterly over three years, with vesting to commence on October 1st, 2026. Additionally, during the Term, you will be

eligible to receive short and long-term equity incentive awards pursuant to the terms of the Company’s Fourth Amended and Restated

2021 Incentive Award Plan (the “2021 Plan”), or any successor plan thereto, which is incorporated herein.

d. Benefits. During your employment with the Company,

you will be eligible for participation in employee health and welfare benefits programs, retirement programs, and other fringe benefits

maintained by the Company, to the extent consistent with applicable law and the terms of the applicable plans and programs available

to similarly situated executives of the Company. The Company retains all rights to amend or terminate any such benefit plans and programs,

subject to the terms of such employee benefit plans and programs and applicable law, and nothing contained herein shall obligate the

Company to continue any benefit plans or programs in the future. You will be entitled to all paid holidays as are observed by the Company,

and twenty (20) days of paid vacation per year (prorated for partial years and pursuant to Company policies), to be taken at times mutually

acceptable to you and the Company.

e. Business Expenses. During the Term, the Company will

reimburse you for reasonable business expenses, including travel, entertainment, and other expenses incurred by you in the furtherance

of the performance of your duties hereunder, in accordance with the Company’s Travel and Entertainment policy as in effect from

time to time. Domestic travel shall be at economy-plus (or better) class, and international travel shall be at business class (or better).

f. All payments made under this Agreement shall be reduced by

any tax or other amounts required to be withheld under applicable law.

g. Place of Duty. You will be allowed to work remotely

full-time from your residence in Tennessee or location of your choice so long as you are present at the Company’s office in Miami

from time to time for business needs as may be reasonably required by the job as requested by the Company.

4. Termination and Severance.

a. Upon your termination of employment for any reason, the Company

shall pay to you (i) your base salary earned through the date of such termination, (ii) amounts for accrued but unused vacation days,

(iii) all compensation and employee benefits, if any, that are due and owing to you under the terms of the Company’s employee benefit

plans and programs, in each case, in accordance with and subject to the terms and conditions of the applicable employee benefit plan,

and (iv) any unreimbursed business expenses to which you would be entitled in accordance with the Company’s reimbursement policy,

not later than thirty (30) business days after the customary documentation regarding such expenses has been received and only to the

extent that such expenses are submitted within one year of your termination (collectively, “Accrued Amounts”). The

Accrued Amounts shall be paid in a lump sum on the first regular payday following the date of termination (or sooner if required by law).

For avoidance of doubt, your rights and obligations with respect to equity awards, if any, shall be controlled by, and subject to, the

terms and conditions set forth in the 2021 Plan or successor plan and the applicable award agreements.

b. In the event your employment is terminated during the Term

by the Company without Cause (as defined below) or by you for Good Reason (as defined below), in addition to the Accrued Amounts, you

will be entitled to receive, subject to your timely execution and non-revocation of a Release (as defined below) (i) any earned but unpaid

bonus for any prior completed fiscal year, payable when such payments would otherwise be paid, (ii) severance benefits in the amount

of three (3) months of your then existing Base Salary for every year you have worked full time for Longeveron in this role (which for

the avoidance of doubt, commenced on August 17, 2026), and prorated for partial years and capped at a maximum of twelve (12) months,

provided, however, that in no case shall the severance benefit under this section be less than three (3) months of your then existing

Base Salary, and further that the severance benefit under this section shall be payable in the form of salary continuation; and (iii)

if you are eligible for and timely elect to continue health benefits under COBRA, the Company will pay the applicable COBRA premiums

until the earlier of: (A) three (3) months for each year you have worked full time for Longeveron (but in no event for less than three

(3) months), and prorated for partial years , and for up to eighteen (18) months of COBRA continuation coverage, or whatever the maximum

period of COBRA coverage may be at that time, whichever is greater; (B) the date you cease to be eligible for COBRA continuation coverage;

or (C) the date you receive substantially equivalent health coverage from another means or employer; and (iv) annual cash bonus

payment for current year, at target level and prorated based on date of termination and payable at the overall corporate goal achievement

level as certified by the Compensation Committee and/or Board and awarded to the other members of the C-Suite (with the 20% discretionary

portion payable or not in the sole discretion of the CEO and/or Compensation Committee and/or Board), and payable when such bonus payments

are actually paid, if at all, to the other C-Suite members.

c. Notwithstanding the foregoing, upon a termination of your

employment by the Company without Cause or by you for Good Reason within six (6) months following a Change in Control (as defined in

the 2021 Plan), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation

of a Release (i) a lump sum payment equal to the sum of twelve (12) months of your base salary as of immediately prior to the Change

in Control and 100% of your then-current annual cash bonus (at target level), (ii) if you are eligible for and timely elect to continue

health benefits under COBRA, the Company will pay the applicable COBRA premiums until the earlier of twelve (12) months following your

termination date, the date you cease to be eligible for COBRA continuation coverage, or the date you receive substantially equivalent

health coverage from another employer; and (iii) full vesting of any equity awards then outstanding held by you (with any performance-based

equity awards vesting at “target” levels) and the exercise period of any stock option continuing for a one-year period following

your termination of employment. Notwithstanding anything to the contrary set forth herein, to the extent that there is a conflict between

any of the terms set forth in this Agreement and any terms set forth in an award agreement relating to the grant of equity awards to

you, the terms of this Agreement shall prevail.

d. In the event that your employment is terminated by the Company

for Cause, or on account of your death, Disability or voluntary resignation, other than for reasons described in subsections (b) or (c)

above, you will not be entitled to receive any payments under this Agreement other than the amounts specified in subsection (a) above.

e. Payment of any severance payments or benefits pursuant to

subsection (b) above is expressly conditioned upon your (i) execution of a general waiver and release of claims in such form and substance

as reasonably required by the Company (the “Release”), within twenty-one (21) days of your termination unless additional

time is required by law, and the Release becoming effective upon the expiration of the revocation period (which is seven days after the

Release is executed and returned to the Company) and (ii) continued compliance with this Agreement and the Covenant Agreement (as defined

below). If an executed Release is not returned to the Company within twenty-one (21) days of termination unless additional time is required

by law or the Release is revoked by you, the Company shall be relieved of all obligations to pay you severance under this Agreement.

The payment described in subsection 4(b)(ii) shall be paid in the form of salary continuation and shall be made in substantially equal

installments, at least monthly, commencing on or before the 60th day following your termination date. The first such payment shall include

payment of all severance benefits that otherwise would have been due prior to such date, applied as though such payments commenced on

the next normal pay date immediately following your termination date. The payment described in subsection 4(c)(i) shall be paid on or

before the 60th day following your termination date.

f. For purposes of this Agreement:

“Cause” shall

include, but not be limited to: (i) the executive’s unauthorized use or disclosure of confidential information or trade secrets

of the Company or any subsidiary, or any material breach of a written agreement between the executive and the Company or any of its subsidiaries,

including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement; (ii)

the executive’s commission of, indictment for or the entry of a plea of guilty or nolo contendere by the executive to, a

felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime

in any jurisdiction outside the United States); (iii) the executive’s gross negligence or willful misconduct which is materially

injurious to the Company or any of its subsidiaries, or the executive’s willful or repeated failure or refusal to substantially

perform material assigned duties; (iv) any act of fraud, embezzlement, material misappropriation or dishonesty committed by the executive

against the Company or any of its subsidiaries; (v) the material violation by the executive of any rule or policy of the Company or any

of its subsidiaries of which the executive had written notice; or (v) any acts, omissions or statements by executive which the Company

reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company

or any subsidiary; provided further that for any “Cause” reasonably capable of cure, “Cause” shall not

exist unless Company has provided executive with written notice of the “Cause,” and executive fails to cure the events or

issues giving rise to the “Cause” within thirty (30) days of Company’s notice.

“Good Reason”

means (i) a change in the executive’s position with the Company that materially reduces the executive’s title, authority,

duties or responsibilities or the level of management to which he or she reports, (ii) a material change in executive’s Place of

Duty, or material diminution in the executive’s level of compensation (including base salary, fringe benefits and target bonuses

under any corporate performance-based incentive programs), excluding any reduction that applies generally to similarly situated employees

of the Company, and excluding any change made in connection with the termination of your employment for Cause, or on account of your death

or Disability, or temporarily as a result of your Disability or other absence for an extended period, provided, that you will not

have the right to resign for Good Reason pursuant to this provision of the Good Reason definition due to a change in authority, duties

or responsibilities solely as a result of the Company no longer being a publicly traded company; and provided further that for

any “Good Reason” reasonably capable of cure, “Good Reason” shall not exist unless executive has provided Company

with written notice of the “Good Reason,” and Company fails to cure the events or issues giving rise to the “Good Reason”

within thirty (30) days of executive’s notice.

g. Effective as of the date of your termination of employment,

unless otherwise requested by the Company in writing, you will, automatically and without further action on your part or any other person

or entity, resign from all offices, boards of directors (or similar governing bodies) and committees of the Company. You agree that you

will, at the request of the Company, execute and deliver such documentation as may be required to effect such resignations, and authorize

any member of the Company to file (or cause to be filed) such documentation, as necessary, with any applicable governmental authority.

h. In consideration for the promises and payments by the Company

pursuant to this Agreement, at the request of the Company, for a one-year period following your termination of employment for any reason,

you agree to cooperate to the fullest extent possible with respect to matters involving any member of the Company about which you have

or may have knowledge, including any such matters which may arise before or after the Term; provided such cooperation shall not

unreasonably interfere with any obligations you may have to your current employer at the time. The Company will compensate you for your

time at a reasonable rate to be agreed to, reimburse you for any reasonable, properly documented out-of-pocket expenses, including your

travel expenses and attorneys’ fees that you actually incur in connection with such cooperation.

i. The Company shall provide Director and Officers (D&O)

insurance coverage from the start date of employment in accordance with its existing policies as applicable to other Section 16 officers.

5. Section 409A. This Agreement is intended to comply

with Section 409A of the Code (“Section 409A”) or an exemption thereunder and shall be administered and interpreted accordingly.

Each payment under this Agreement, including each installment payment, shall be considered a separate and distinct payment. For purposes

of this agreement, each payment is intended to be excepted from Section 409A to the maximum extent provided as follows: (i) each payment

made within the applicable 2½ month period specified in Treas. Reg.§ 1.409A-1(b)(4) is intended to be excepted under the

short-term deferral exception; (ii) post-termination medical benefits are intended to be excepted under the medical benefits exceptions

as specified in Treas. Reg. § 1.409A-1(b)(9)(v)(B); and (iii) to the extent payments are made as a result of an involuntary separation,

each payment that is not otherwise excepted under the short-term deferral exception or medical benefits exception is intended to be excepted

under the involuntary pay exception as specified in Treas. Reg. § 1.409A-1(b)(9)(iii). With respect to any payment subject to Section

409A (and not excepted therefrom), if any, it is intended that each payment is paid on a permissible distribution event and at a specified

time consistent with Section 409A. You shall have no right to designate the date of any payment under this Agreement. In the event the

terms of this Agreement would subject you to the imposition of taxes and penalties under Section 409A (“409A Penalties”),

the Company and you shall cooperate diligently to amend the terms of this Agreement to avoid such 409A Penalties, to the extent possible;

provided that, for the avoidance of doubt, you shall be solely liable for any 409A Penalties incurred by you.

All references in this Agreement to

your termination of employment shall mean your “separation from service” within the meaning of Section 409A of the Code and

Treas. Reg. § 1.409A-1(h). Whether you have had a separation from service will be determined based on all of the facts and circumstances

and in accordance with the guidance issued under Section 409A.

Notwithstanding any other provision of

this Agreement to the contrary, if any payment or benefit provided to you in connection with your termination of employment is determined

to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are determined by the Company

to be a “specified employee” as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the

first payroll date following the six-month anniversary of your termination date or, if earlier, on your death (the “Delayed Payment

Date”). The aggregate of any payments that would otherwise have been paid before the Delayed Payment Date shall be paid (without

interest) to you (or your estate or beneficiaries) in a lump sum on the Delayed Payment Date and thereafter, any remaining payments shall

be paid without delay in accordance with their original schedule.

With respect to any taxable expense

reimbursements, in-kind benefits and/or cash allowances provided or paid by the Company under this Agreement, such reimbursement shall

be made in accordance with and subject to the following terms and conditions: (i) reimbursements shall only be made to the extent that

the expense was actually incurred and reasonably substantiated; (ii) reimbursements of eligible expenses shall be made on or before the

last day of your taxable year following the taxable year in which you incurred the expense; (iii) the amount of any expenses eligible

for reimbursement or the amount of any in-kind benefits provided, as the case may be, under this Agreement during any calendar year shall

not affect the amount of expenses eligible for reimbursement or the amount of any in-kind benefits provided during any other calendar

year; and (iv) the right to reimbursement or to any in-kind benefit pursuant to this Agreement shall not be subject to liquidation or

exchange for any other benefit.

Notwithstanding any provision of this

Agreement to the contrary, you acknowledge and agree that the Company and its employees, officers, directors and affiliates are not providing

you with any tax advice with respect to Section 409A of the Code or otherwise and are not making any guarantees or other assurances of

any kind to you with respect to the tax consequences or treatment of any amounts paid or payable to you under this Agreement. Nothing

provided or contained in this Agreement will be construed to obligate or cause the Company and/or its employees, officers, directors,

subsidiaries and affiliates to be liable for, any tax, interest or penalties imposed on you related to or arising with respect to any

violation of Section 409A.

6. Section 280G. If the present value of your severance

benefits, either alone or together with other payments which you have the right to receive from the Company (the “Benefits”)

constitute a “parachute payment” as defined in Section 280G of the Code, then your Benefits shall be either (i) provided

to you in full, or (ii) provided to you only as to such lesser extent that would result in no portion of such Benefits being subject

to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), whichever of the foregoing amounts, taking into

account the applicable federal, state, and local income and employment taxes and the Excise Tax, results in the receipt by you, on an

after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such Benefits may be taxable under the

Excise Tax.

Unless the Company and you otherwise

agree, any determination required under section shall be made in writing in good faith by the Company’s independent accounting firm

or such other nationally or regionally recognized accounting firm selected by the Company (the “Accountants”), whose determination

shall be conclusive and binding upon you and the Company for all purposes. In the event that a reduction to the Benefits under this section,

the reduction shall apply first to the Benefits that are not deferred compensation subject to Section 409A of the Code and you shall be

given the choice, subject to approval by the Company, of which of such Benefits to reduce; provided, that such reduction achieves the

result specified in clause (ii) above of this section. If a reduction in the Benefits that are subject to Section 409A of the Code is

required, such Benefits shall be reduced pro rata, but with no change in the time at which such Benefits shall be paid. For purposes of

making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable

taxes and may rely on reasonable, good faith interpretations concerning the application of the Code. The Company and you shall furnish

to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this

section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this

section.

7. Restrictive Covenant Obligations. You acknowledge

and agree that you will be subject to the Company’s existing policies regarding confidentiality, non-disclosure, non-use, non-competition,

non-solicitation or other covenants pursuant to the terms of that certain Confidentiality and Nondisclosure Agreement with the Company,

which has been or shall be executed prior to the Effective Date (the “Covenant Agreement”). Notwithstanding any provision

in this Agreement, the Covenant Agreement or otherwise to the contrary, nothing in this Agreement, the Covenant Agreement or otherwise

precludes or otherwise limits your ability to (A) communicate directly with and provide information, including documents, not otherwise

protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the “SEC”) or any

other federal, state or local governmental agency or commission (“Government Agency”) or self-regulatory organization regarding

possible legal violations, without disclosure to the Company, or (B) disclose information which is required to be disclosed by applicable

law, regulation, or order or requirement (including without limitation, by deposition, interrogatory, requests for documents, subpoena,

civil investigative demand or similar process) of courts, administrative agencies, the SEC, any Government Agency or self-regulatory

organizations, provided that, if permissible by law, you provide the Company with prior notice of the contemplated disclosure and cooperate

with the Company in seeking a protective order or other appropriate protection of such information. The Company may not retaliate against

you for any of these activities.

8. Representation Regarding Prior Commitment. You

represent that your performance of all of the terms of this Agreement and the performance of the services for the Company does not and

will not breach or conflict with any agreement with a third party, including an agreement not to compete or to keep in confidence any

proprietary information of another entity acquired by you in confidence or in trust prior to the date of this Agreement. You agree that

you will not enter into any agreement that conflicts with this Agreement during the term of your employment with the Company.

9. Governing Law, Forum and Venue. This Agreement

shall be governed, construed, interpreted and enforced in accordance with its express terms, and otherwise in accordance with the substantive

laws of the State of Florida, without reference to the principles of conflicts of law or choice of law of the State of Florida, or any

other jurisdiction, and where applicable, the laws of the United States. All questions pertaining to the validity, construction, execution

and performance of this Agreement shall be construed and governed in accordance with the laws of the State of Florida, without giving

effect to principles of conflicts or choice of law. Jurisdiction and venue for any disputes shall be, as appropriate, in the state courts

in Miami-Dade County, FL, or the federal courts in the Southern District of Florida.

EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY

WAIVES ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED

HEREBY.

10. Validity. The invalidity or unenforceability of

any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement,

which shall remain in full force and effect. You were advised to seek counsel with regard to this Agreement and all employment terms,

and you were represented by counsel.

11. Final Agreement. The terms of this Agreement and

the Covenant Agreement are intended by the parties to be the final expression of their agreement with respect to your employment by the

Company and supersede, effective as of the Effective Date, all prior understandings and agreements with respect to your employment by

the Company, whether written or oral. For the avoidance of doubt, if the Effective Date does not occur, this Agreement will be void ab

initio. Any other signed written agreements, including referenced herein that are not in contradiction with this Agreement are in

full force and effect.

12. Assignment. The rights and benefits under this

Agreement are personal to you and such rights and benefits shall not be subject to assignment, alienation or transfer, except to the

extent such rights and benefits are lawfully available to your estate or any of your beneficiaries upon your death. The Company may assign

this Agreement to any affiliate or subsidiary at any time and shall require any entity which at any time becomes a successor, whether

by merger, purchase, or otherwise, or otherwise acquires all or substantially all of the assets, membership interests or business of

the Company, to expressly assume this Agreement.

13. Counterparts. This Agreement may be executed in

several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.

Signatures delivered by facsimile shall be deemed effective for all purposes.

[Signature page follows]

Please sign and date this Agreement in

the space indicated and return it to my attention to evidence your understanding and acceptance of the terms set forth herein.

Sincerely,

Longeveron Inc.

By:

/s/ Stephen Willard

Stephen Willard, CEO

Agreed to and Accepted:

By:

/s/ Nirav Jhaveri

Nirav Jhaveri

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: ea030272301ex99-1.htm · Sequence: 3

Exhibit 99.1

Longeveron Appoints Nirav Jhaveri as Chief Financial

Officer

● Mr. Jhaveri has over 25 years of experience in capital markets, corporate

finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Fla., August 19, 2026 -- Longeveron Inc.

(NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related

conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the

role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn

who stepped into the role following the retirement of the prior CFO. Ms. Washburn will return to her former role as the Company’s

Corporate Controller.

“I am delighted to welcome Nirav as Longeveron’s

Chief Financial Officer,” said Steven H. Willard, Chief Executive Officer of Longeveron. “His significant experience in biotech

company corporate finance and capital markets will be a tremendous asset as Longeveron continues to advance the development of our stem

cell therapy across four indications, each addressing a significant unmet medical need. Our Phase 2b clinical trial evaluating laromestrocel

as a potential treatment for HLHS, a devastating rare pediatric and orphan designated indication, is anticipated to produce top-line trial

results in September of this year.”

Mr. Jhaveri commented, “I am incredibly

excited to join the Company at this potentially transformational period in its history. With strong initial data across multiple indications,

I believe Longeveron is well positioned to be a leader in advancing the adoption of stem cell therapy in healthcare. I look forward to

working closely with Steve, the Board of Directors and the entire Longeveron team to ensure the long-term success of laromestrocel while

enhancing the Company’s operational functions.”

Mr. Jhaveri has served as Chief Financial Officer

at public and venture-backed biotech companies, with over 25 years of experience in capital markets, corporate finance, business development,

and investor relations, including over 15 years in the biotech sector, and a track record across capital raising, licensing and M&A

transactions, and IPO readiness.

Before joining Longeveron, Mr. Jhaveri served

as CFO of Opus Genetics (Nasdaq: IRD), a gene therapy company focused on inherited retinal diseases; Insilico Medicine (HKEX: 3696.HK),

an AI-driven drug discovery company; and Journey Medical Corporation (Nasdaq: DERM), a commercial-stage dermatology company. Earlier in

his career, Mr. Jhaveri held roles in business development at Fortress Biotech, equity research at Citigroup, and investment banking at

Bank of America. He is a CFA (Chartered Financial Advisor) charterholder.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology

company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel

(Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors.

Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue

repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline

indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related

Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan

Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced

Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn,

X, and Instagram.

Forward-Looking Statements

Certain statements in this press release that

are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation

Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance

and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results,

performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking

statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,”

“contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,”

“looks to,” “may,” “on condition,” “plan,” “potential,” “predict,”

“preliminary,” “project,” “see,” “should,” “target,” “will,” “would,”

or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of

strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from

those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of our clinical

trials to demonstrate safety and efficacy of our investigational products, and other positive results; our ability to successfully transition

toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our

stem cell therapy laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities

on a potential path toward regulatory approval of our investigational products; receipt of trial results and other available evidence

sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of

our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other

conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the

dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which

we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;

the size of the market opportunity for certain of our investigational products, including our estimates of the number of patients who

suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational products for certain

indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and

therapeutic effects of our investigational products; our ability to obtain and maintain regulatory approval of our investigational products

in the U.S. and other jurisdictions; our plans relating to the further development of our investigational products, including additional

disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions

of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire

additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital

requirements and needs for additional financing.

Further information relating to factors that may

impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and

Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities

and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates

in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s

management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor

or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking

statements contained in this press release are made as of the date of this press release based on information available as of the date

of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to

update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions

derek.cole@iradvisory.com

###

GRAPHIC

Filename: ea030272301_ex10-1img1.jpg · Sequence: 4

Binary file (1686 bytes)

Download ea030272301_ex10-1img1.jpg

GRAPHIC

Filename: ea030272301_ex99-1img1.jpg · Sequence: 5

Binary file (3019 bytes)

Download ea030272301_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.1

Cover

Aug. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 17, 2026

Entity File Number

001-40060

Entity Registrant Name

Longeveron Inc.

Entity Central Index Key

0001721484

Entity Tax Identification Number

47-2174146

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1951 NW 7th Avenue

Entity Address, Address Line Two

Suite 520

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33136

City Area Code

305

Local Phone Number

909-0840

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Common Stock, $0.001 par value per share

Trading Symbol

LGVN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration